Assessment of HIV testing of urban injection drug users: Implications for expansion of HIV testing and prevention efforts

American Journal of Public Health

Volumn 97, Issue 1, 2007, Pages 110-116

  Heimer, Robert ^a   Grau, Lauretta E ^a   Curtin, Erin ^c   Khoshnood, Kaveh ^a   Singer, Merrill ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HISPANIC HEALTH COUNCIL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ETHNICITY; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RACE; SCREENING TEST; SECONDARY PREVENTION; SELF REPORT; SEX RATIO; SYRINGE EXCHANGE PROGRAM; UNITED STATES; URBAN POPULATION;

ADULT; AIDS SERODIAGNOSIS; BLOOD-BORNE PATHOGENS; DIAGNOSTIC SERVICES; EQUIPMENT CONTAMINATION; FEMALE; HEALTH EDUCATION; HIV SEROPOSITIVITY; HIV SEROPREVALENCE; HUMANS; MALE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; PROGRAM EVALUATION; PUBLIC HEALTH ADMINISTRATION; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES; UNITED STATES; URBAN HEALTH SERVICES;

EID: 33846047496     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2005.078105     Document Type: Article

References (59)

1. Fleming P, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States, 2000. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 25, 2002; Seattle, Wash.
2. Janssen RS, Onorato IM, Valdiserri RO, et al. Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;52:329-332.
3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2003. Atlanta, Ga: US Dept of Health and Human Services; 2004.
4. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998;88:108-113.
5. Division of HIV/AIDS Prevention Centers for Disease Control and Prevention. Advancing HIV Prevention: New Strategies for a Changing Epidemic. Available at: http://www.cdc.gov/hiv/partners/AHP-brochure.htm. Accessed July 15, 2005.
6. Anderson JE, Carey JW, Taveras S. HIV testing among the general US population and persons at increased risk: information from national surveys, 1987-1996. Am J Public Health. 2000;90:1089-1095.
7. HIV Testing Survey. HIV/AIDS Special Surveillance Report 5. Atlanta, Ga: Centers for Disease Control and Prevention; 2002.
8. Kellerman SE, Lehman JS, Lansky A, et al. HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing. J Acquir Immune Defic Syndr. 2002;31:202-210.
9. Marks G, Crepaz N, Senterfritt W, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446-453.
10. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. New Engl J Med. 2005;352:570-585.
11. Paltiel AD, Weinstein MC, Rimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. New Engl J Med. 2005;352:586-595.
12. Bozzette SA. Routine screening for HIV infection-timely and cost-effective. New Engl J Med. 2005;352:620-621.
13. US Preventive Services Task Force. Screening for HIV: recommendation statement. Ann Intern Med. 2005;143:32-37.
14. Heimer R, Clair S, Grau LE, Bluthenthal RN, Marshall PA, Singer M. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction. 2002;97:1277-1287.
15. Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall PA, Heimer R. Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities. Addiction. 2004;99:1136-1146.
16. Heimer R, Clair S, Teng W, Grau LE, Khoshnood K, Singer M. Effects of increasing syringe availability on syringe-exchange use and HIV risk: Connecticut 1990-2001. J Urban Health. 2002;79:556-570.
17. Buchanan D, Shaw S, Teng W, Hiser P, Singer M. Neighborhood differences in patterns of syringe access use, and discard among injection drug users: implications for HIV outreach and prevention education. J Urban Health. 2003;80:438-454.
18. Singer M, Stopka T, Shaw S, et al. Lessons from the field: from research to application in the fight against AIDS among injection drug users in three New England cities. Hum Organ. 2005;64:179-191.
19. National Institute on Drug Abuse. Risk Behavior Assessment. Rockville, MD: National Institutes of Health, Dept of Health and Human Services; 1991.
20. Grund JP, Kaplan CD, Adriaans NF, Blanken P, Huisman J. The limitations of the concept of needle sharing: the practice of frontloading. AIDS. 1990;4:819-821.
21. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9:27-39.
22. Watters JK, Bluthenthal RN, Kral AH. HIV sero-prevalence in injection drug users. JAMA. 1995;273:1178.
23. Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). J Acquir Immune Defic Syndr. 2000;25:63-70.
24. Friedman SR, Tempalski B, Cooper H, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81:377-400.
25. Ziek K, Goldstein MF, Beardsley M, Deren S, Tortu S. Factors associated with HIV testing and returning for test results in a sample of out-of-treatment drug users. J Drug Issues. 2000;30:675-686.
26. Samet JH, Mulvey KP, Zaremba N, Plough A. HIV testing in substance abusers. Am J Drug Alcohol Abuse. 1999;25:269-280.
27. Kral AH, Lorvick J, Gee L, et al. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidermiol. 2003;157:915-922.
28. Quellet LJ, Thorpe LE, Huo D, et al. Prevalence and incidence of HIV among out-of-treatment injecting drug users, Chicago 1994-1996. J Acquir Immune Defic Syndr. 2000;25:443-450.
29. Nelson KE, Galai N, Safaeian M, Strathdee SA, Celentano DD, Vlahov D. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol. 2002;156:641-653.
30. Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003;157:467-471.
31. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:175-176.
32. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HW, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94:1218-1223.
33. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001;153:619-627.
34. Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95:1439-1444.
35. Collier K, Kotranski L, Semaan S, Lauby J, Halbert J, Feighan K. Correlates of HIV seropositivity and HIV testing among out-of-treatment drug users. Am J Drug Alcohol Abuse. 1998;24:377-393.
36. Tobin KE, Tang AM, Gilbert SH, Latkin CA. Correlates of HIV antibody testing among a sample of injection drug users: the role of social and contextual factors. AIDS Behav. 2004;8:303-310.
37. Vernon KA, Mulia N, Downing M, Knight K, Riess T. "I don't know when it might pop up": understanding repeat HIV testing and perceptions of HIV among drug users. J Subst Abuse. 2001;13:215-227.
38. Riess TH, Kim C, Downing M. Motives for HIV testing among drug users: an analysis of gender differences. AIDS Educ Prev. 2001;13:509-523.
39. Davis WR, Deren S, Beardsley M, Wenston J, Tortu S. Gender differences and other factors associated with HIV testing in a national sample of active drug injectors. AIDS Educ Prev. 1997;9:342-358.
40. Liebman J, Brooks D, Bonilla L, Kotranski L. Utilization of HIV antibody testing by out-of-treatment drug users. J Drug Issues. 1996;26:679-693.
41. Wurcel A, Zaman T, Zhen S, Stone D. Acceptance of HIV antibody testing among inpatients and outpatients at a public health hospital: a study of rapid versus standard testing. AIDS Patient Care STDS. 2005;19:499-505.
42. Spielberg F, Branson BM, Goldbaum GM, et al. Choosing HIV counseling and testing strategies for outreach settings: a randomized trial. J Acquir Immune Defic Syndr. 2005;38:348-355.
43. Anonymous. Supplemental testing for confirmation of reactive oral fluid rapid HIV antibody tests. MMWR [dispatch]. 2005;54:1287-1288.
44. Ekwueme DU, Pinkerton SD, Holtgrave DR, Branson BM. Cost comparison of three HIV counseling and testing technologies. Am J Prev Med. 2003;25:112-121.
45. Thorpe LE, Bailey SL, Huo D, Monterroso ER, Quellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr. 2001;27:71-78.
46. Des Jarlais DC, Perlis T, Arasteh K, et al. "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr. 2004;35:158-166.
47. Heimer R, Khoshnood K, Buchanan D, et al. Syringe exchange, community coverage, declining AIDS rates. Paper presented at: 2005 National HIV Prevention Conference; June 13, 2005; Atlanta, Ga.
48. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11:F59-F65.
49. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17:887-893.
50. "HIV-infection" Information Bulletin No. 1 [in Russian]. Russian Federal AIDS Center; 1994. In: Gardner KJ. HIV Testing and the Law in Russia; 1996. Available at: http://www.openweb.ru/aesop/eng/hiv-hr/hiv. html. Accessed May 25, 2005.
51. Rhodes T, Sarang A, Bobrik A, Bobkov A, Platt L. HIV transmission and HIV prevention associated with injecting drug use in the Russian Federation. Int J Drug Policy. 2004;15:1-16.
52. National Institutes of Health Consensus Development Program. Interventions to prevent HIV risk behaviors. Bethesda, Md: National Institutes of Health; 1997. Report 104.
53. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1)5133-5138.
54. Pollack HA, Heimer R. Impact and cost-effectiveness of methadone maintenance programs for HIV and hepatitis C prevention. In: Weissing L, ed. Impact and Costs of Hepatitis C in Injecting Drug Users in the European Union. Utrecht Netherlands: European Monitoring Centre for Drugs and Drug Addiction; 2003.
55. Wood E, Montaner JS, Bangsberg DR, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003;17:2419-2427.
56. Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health, 2003;30:416-427.
57. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis. 2004;38(suppl 5):S376-S387.
58. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodefiniciency virus infection. Am J Epidemiol. 2005;161:999-1012.
59. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis. 2004;190:1046-1054.